The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. This year’s metric has recorded a Price increase of 2.69%. However, over the past six months, we’ve seen a stronger performance of -33.70%. The price of PACB fallen by 12.90% over the last 30 days. And in the last five days, it has surged by 28.83%.
Currently, the stock price of Pacific Biosciences of California Inc (PACB) is $8.40. In the most recent trading session, the stock underwent a significant upswing, peaking at $8.445 after opening at $7.82. The stock touched a low of $7.705 before closing at $7.59.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Pacific Biosciences of California Inc’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $14.55 on 07/18/23, and the lowest price during that time was $5.74, recorded on 11/01/23.
52-week price history of PACB Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Pacific Biosciences of California Inc’s current trading price is -42.27% away from its 52-week high, while its distance from the 52-week low is 46.34%. The stock’s price range over this timeframe has been between $5.74 and $14.55. The shares of the Healthcare sector company recorded a trading volume of approximately 8.64 million for the day, which was comparatively higher than the average daily volume of 4.53 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Pacific Biosciences of California Inc (PACB) has experienced a quarterly decline of -18.84% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.25B and boasts a workforce of 769 employees.
Expert Opinions: Analysts’ Ratings for Pacific Biosciences of California Inc
As of right now, 7 analysts are rating Pacific Biosciences of California Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 4 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 10.07, with a change in price of -4.60. Similarly, Pacific Biosciences of California Inc recorded 4,226,984 in trading volume during the last 100 days, posting a change of -35.38%.
PACB’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for PACB stands at 1.22. Similarly, the long-term debt-to-equity ratio is also 1.21.
PACB Stock Stochastic Average
Pacific Biosciences of California Inc’s raw stochastic average for the past 50 days is currently at 42.80%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 98.34%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 92.72% and 78.64%, respectively.
